Maximise product value through Medical Insights

The healthcare industry is at an inflection point with constant pressure on margins and limited opportunities to maximise asset value from highly complex technologies such as CAR-T and mRNA.

Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.

At Deallus, we believe that intelligence and insights are capabilities that are continuously evolving and remain a critical element for adapting an organisation towards upcoming market events, for building resilience, driving competitive readiness, and enhancing asset strategic planning.

Typically, Medical Insights value proposition covers:

  • Harnessing cross functional capabilities to generate insights through medical channels

  • Articulation of clinical, humanistic, and financial insights to maximise product value

  • Capturing real-world insights from MSL, MI, and clinical development teams

  • Identifying evidence gaps and assess mitigation plans during strategic planning

  • Supporting evidence generation enablement and cataloging
  • Supplementing RWE data used within commercialisation through field insights and enhancing partnerships for evidence generation

Download to read more.


You may also be interested in…

Deallus sponsoring and speaking at the Pharma CI EU Conference

We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.

  • Policies for rare diseases in China Feb 2023

Overview of current policy for rare disease in China

For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.

  • HIV & AIDS Medication


Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).

  • Deallus Workshops

Deallus Workshops: providing competitive advantage through Competitive Simulation

Competitive Simulation, also known as Competitive Strategy or ‘Wargaming’ workshops, account for roughly 85% of the workshops that Deallus run. We have developed a detailed and comprehensive workshop playbook that ensures our teams are well-prepared and well-versed with a set of tools ready to run your sessions.